Article    Table of Contents                    Full Text of this article Free    Figures/Tables List  Services    Send comment/rapid response letter    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search                            Get Permissions  Google Scholar    Search for Related Content  PubMed Articles in PubMed by Author:    Bray, G. A.    Related Articles in PubMed    PubMed Citation    PubMed

METHODS FOR VOLUNTARY WEIGHT LOSS AND CONTROL: NATIONAL INSTITUTES OF HEALTH TECHNOLOGY ASSESSMENT CONFERENCE

Use and Abuse of Appetite-suppressant Drugs in the Treatment of Obesity

George A. Bray

1 October 1993 | Volume 119 Issue 7 Part 2 | Pages 707-713

Most of the available appetite-suppressant drugs act on noradrenergic and possibly dopaminergic receptors to produce satiety. A smaller number increase excess neuronal serotonin levels by blocking serotonin reuptake or by increasing its release. All these drugs produce significantly greater weight loss than does placebo in most studies. Abuse is a problem with amphetamine, methamphetamine, and benzphetamine, whereas other drugs have minimal or no potential for abuse. Weight loss can be sustained for up to 36 months. Net weight loss, compared with placebo, ranges from 2 to 10 kg, and weight regain after terminating drug treatment proves that drugs do not work when not taken. The stigma of obesity, the public opprobrium toward obese persons, and regulatory rigidity have led to unjustified distrust in the potential of drug treatment for obesity.

Author and Article Information

From Pennington Biomedical Research Center and Louisiana State University, Baton Rouge, Louisiana.
Requests for Reprints: George A. Bray, MD, Pennington Biomedical Research Center, 6400 Perkins Road, Baton Rouge, LA 70808.

This article has been cited by other articles:

				A. M. Sharma Does pharmacologically induced weight loss improve cardiovascular outcome? Sibutramine pharmacology and the cardiovascular system Eur. Heart J. Suppl., November 1, 2005; 7(suppl_L): L39 - L43. [Abstract] [Full Text] [PDF]

				A. N. Fabricatore and T. A. Wadden Treatment of Obesity: An Overview Clin. Diabetes, April 1, 2003; 21(2): 67 - 72. [Abstract] [Full Text] [PDF]

				M. Steelman, W. P. Weiss, F. Maese, M. Lechin, S. Z. Yanovski, and J. A. Yanovski Pharmacotherapy for Obesity N. Engl. J. Med., June 27, 2002; 346(26): 2092 - 2093. [Full Text] [PDF]

				P. Kearns Are There Benefits From Long-term Pharmacotherapy of Obesity? Arch Intern Med, May 13, 2002; 162(9): 1070 - 1070. [Full Text] [PDF]

				A. M. Rodrigues, R. B. Radominski, H. d. L. Suplicy, S. M. De Almeida, P. A. Niclewicz, and C. L. Boguszewski The Cerebrospinal Fluid/Serum Leptin Ratio during Pharmacological Therapy for Obesity J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1621 - 1626. [Abstract] [Full Text] [PDF]

				C. I. Volume and K. B. Farris Hoping to Maintain a Balance: The Concept of Hope and the Discontinuation of Anorexiant Medications Qual Health Res, March 1, 2000; 10(2): 174 - 187. [Abstract] [PDF]

				G. A. Bray and F. L. Greenway Current and Potential Drugs for Treatment of Obesity Endocr. Rev., December 1, 1999; 20(6): 805 - 875. [Abstract] [Full Text]

				D. A. Anderson and T. A. Wadden Treating the Obese Patient: Suggestions for Primary Care Practice Arch Fam Med, March 1, 1999; 8(2): 156 - 167. [Abstract] [Full Text] [PDF]

				S. B. Heymsfield, D. B. Allison, J. R. Vasselli, A. Pietrobelli, D. Greenfield, and C. Nunez Garcinia cambogia (Hydroxycitric Acid) as a Potential Antiobesity Agent: A Randomized Controlled Trial JAMA, November 11, 1998; 280(18): 1596 - 1600. [Abstract] [Full Text] [PDF]